Two patients (VEGF <100 pg ml−1) received systemic nitrosourea therapy (one melanoma, one glioblastoma) and remained neurologically stable; one patient (VEGF <100 pg ml−1) received intrathecal MTX (one chronic lymphocytic leukaemia). This evidence concerns the gene VEGFA and B-cell chronic lymphocytic leukemia.